In vitro activities of ABT-492, ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin were compared. ABT-492 was more potent against quinolone-susceptible and -resistant grampositive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. Bactericidal activity of ABT-492 was also evaluated.
Antimicrobial resistance continues to be problematic. Resistance rates in other U.S. studies were examined. More than 30% of Streptococcus pneumoniae clinical isolates are penicillin nonsusceptible, and approximately 25% are macrolide resistant (7, 10) . In Haemophilus influenzae, ␤-lactamase-mediated ampicillin resistance is about 28% (11) . In uncomplicated urinary tract infections, 10 to 20% of Escherichia coli isolates are resistant to trimethoprim-sulfamethoxazole and 33 to 40% are resistant to ampicillin (8, 13) . Methicillin resistance in nosocomial Staphylococcus aureus has increased from 2.1% to 26-44%, and methicillin-resistant S. aureus (MRSA) is becoming a problem in community-acquired infections (1, 9, 22, 23) .
Fluoroquinolones have broad-spectrum activity. Newer quinolones demonstrate increased potency against S. pneumoniae, staphylococci, H. influenzae, and some enterococci and have a potency equivalent to that of ciprofloxacin against members of the family Enterobacteriaceae (3, 5, 12, 15, 16) . In the United States, quinolone resistance remains low in S. pneumoniae and has been reported only rarely in H. influenzae (2, 6, 14, 25) .
ABT-492 is a new fluoroquinolone with increased activity, compared to levofloxacin, trovafloxacin, and ciprofloxacin, against gram-positive organisms and activity similar to that of ciprofloxacin against certain gram-negative, quinolone-susceptible and -resistant organisms (20) . The in vitro activities of ABT-492, moxifloxacin, gatifloxacin, gemifloxacin, levofloxacin, trovafloxacin, and ciprofloxacin were evaluated against 919 quinolone-susceptible and -resistant gram-positive and gramnegative pathogens. MIC ranges and MICs inhibiting 50% (MIC 50 ) and 90% (MIC 90 ) of the tested strains are shown in Table 1 . Time-kill analyses of ABT-492, ciprofloxacin, and moxifloxacin were also performed.
Clinical isolates dating from 1983 to 2000 from the Abbott culture collection and reference strains from the American Type Culture Collection (Manassas, Va.) were tested. Strains were classified as quinolone susceptible or resistant on the basis of levofloxacin or ciprofloxacin susceptibility for grampositive and gram-negative organisms, respectively, according to the interpretive criteria of the National Committee for Clinical Laboratory Standards (NCCLS) (17) .
ABT-492 and comparator quinolones were synthesized at Abbott Laboratories (Abbott Park, Ill.). Penicillin and oxacillin were purchased from Sigma Chemical Company (St. Louis, Mo.).
MIC determinations and quality control tests were performed by the NCCLS broth microdilution method and interpreted according to NCCLS-defined breakpoints (17, 18) .
The molecular mechanisms of quinolone resistance were identified by PCR amplification and DNA sequence analysis of the gyrA and grlA/parC genes for the S. aureus, S. pneumoniae, and E. coli strains used in time-kill studies (1, 4, 21, 26) .
Kill kinetics of selected quinolone-susceptible and -resistant strains of S. aureus, S. pneumoniae, E. coli, and Pseudomonas aeruginosa were determined by NCCLS methods at four and eight times the MICs of ABT-492, ciprofloxacin, and moxifloxacin (19) . Starting MICs were determined by the NCCLS broth microdilution method (18) . Colony counts were performed. To determine if there were antibiotic carryover effects of ABT-492, ciprofloxacin, and moxifloxacin, experiments were performed as previously described (19, 24) . No antibiotic carryover effects of ABT-492 and ciprofloxacin were observed. For quinolone-susceptible P. aeruginosa, there was a 10-fold decrease in the number of CFU per milliliter in the moxifloxacin plate counts at eight times the MIC when bacteria were plated immediately compared to the control (no drug), which was reproducible upon additional testing, suggesting a possible antibiotic carryover effect for this strain only. The kill kinetic for this strain showed that all three quinolones were rapidly bactericidal.
ABT-492 and gemifloxacin were the most potent quinolones against quinolone-susceptible and -resistant gram-positive organisms. ABT-492 MIC 90 s were 0.008 to 1 g/ml for quino- Oxacillin susceptibility did not affect ABT-492 activity (MIC 90 ϭ 0.06 g/ml) among oxacillin-susceptible S. aureus isolates. Sixteen and 92% of the oxacillin-susceptible and -resistant strains, respectively, were quinolone resistant. The ABT-492 MIC 90 was 1 g/ml for oxacillin-and quinolone-resistant S. aureus.
Likewise, ABT-492 activity against E. faecalis and E. faecium was unaffected by vancomycin susceptibility. The ABT-492 MIC 90 was 8 g/ml against vancomycin-susceptible E. faecalis and E. faecium and vancomycin-resistant E. faecium, and the MIC range was 0.12 to 0.5 g/ml for vancomycin-resistant E. faecalis (data not shown).
ABT-492 (MIC 90 , Յ0.004 g/ml) was the most potent quinolone against quinolone-susceptible H. influenzae and Moraxella catarrhalis.
Against members of the family Enterobacteriaceae, ABT-492 (MIC 90 s ϭ 0.06 to 0.5 g/ml) and ciprofloxacin (MIC 90 s ϭ 0.06 to 1 g/ml) had equivalent activities for quinolone-susceptible E. coli, Klebsiella spp., Providencia spp., and Proteus spp. Ciprofloxacin (MIC 90 s ϭ 0.015 to 0.25 g/ml) had improved activity, compared to that of ABT-492 (MIC 90 s ϭ 0.06 to 0.2 g/ml), against quinolone-susceptible Enterobacter spp., Salmonella spp., Serratia marcescens, and Citrobacter freundii. ABT-492 (MIC 90 s ϭ 4 to 8 g/ml) was the most potent quinolone against quinolone-resistant E. coli and K. pneumoniae. ABT-492 (MICs ϭ 32 to 128 g/ml) had no activity against four isolates of quinolone-resistant Enterobacter spp.
ABT-492 (MIC 90s ϭ 0.25 to 2 g/ml) and the other quinolones had comparable activity against quinolone-susceptible P. aeruginosa, Stenotrophomonas maltophilia, Acinetobacter spp., and the single isolate of Burkholderia cepacia. None were active against quinolone-resistant P. aeruginosa, Acinetobacter spp., or B. cepacia.
For quinolone-susceptible strains, ABT-492, ciprofloxacin, and moxifloxacin at four and eight times the MICs were bactericidal (Ն3-log 10 decrease [99.9% killing] in the number of CFU per milliliter compared to that of the starting inoculum) for all three drugs at both concentrations within 4 h for S. aureus, E. coli, and P. aeruginosa and within 10 h for S. pneumoniae.
ABT-492 and moxifloxacin were bactericidal at both four and eight times the MICs of both drugs for quinolone-resistant strains of E. coli (GyrA, Ser83-Leu and Asp87-Asn; ParC, Ser80-Ile) (ABT-492 only; moxifloxacin MIC, Ն32 g/ml) within 6 h, S. aureus (GyrA, Ser84-Leu; GrlA, Ser80-Phe) within 10 h, and S. pneumoniae (GyrA, Ser81-Phe; ParC, Ser79-Phe) by 24 h. Ciprofloxacin was not evaluated (MIC, Ն64 g/ml).
ABT-492 is a broad-spectrum quinolone displaying improved in vitro and bactericidal activities against a variety of quinolone-susceptible and -resistant gram-positive and gramnegative organisms, which suggests that it may be useful for treating many different types of infections. 
